Role of integrin alpha4 in drug resistance of leukemia

Frontiers in Oncology

Volumn 4 MAY, Issue , 2014, Pages

  Shishido, Stephanie ^a   Bönig, Halvard ^b   Kim, Yong Mi ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Acute lymphoblastic leukemia; Adhesion; CD49d; Drug resistance; Integrin alpha4

Indexed keywords

AJM 300; ALPHA4 INTEGRIN; ANTIASTHMATIC AGENT; BIO 1211; BIO 5192; COMPOUND 7N; FIRATEGRAST; FOCAL ADHESION KINASE; GASTROINTESTINAL AGENT; HMR 1031; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN LINKED KINASE; IVL 745; LLP 2A; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; NATALIZUMAB; OSTEOPONTIN; PAXILLIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; TBC 3486; THI 0019; UNCLASSIFIED DRUG; VALATEGRAST; VASCULAR CELL ADHESION MOLECULE 1; VEDOLIZUMAB; VERY LATE ACTIVATION ANTIGEN 4; ZAURATEGRAST;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTHRITIS; ASTHMA; BONE MARROW CELL; CELL ADHESION MEDIATED DRUG RESISTANCE; CELL CONTACT; CROHN DISEASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; INFLAMMATORY BOWEL DISEASE; INTRACELLULAR SIGNALING; LIGAND BINDING; MINIMAL RESIDUAL DISEASE; MULTIPLE SCLEROSIS; PHYSICAL SENSITIVITY; RESPIRATORY TRACT INFLAMMATION; REVIEW; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

EID: 84904612896     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00099     Document Type: Review

References (114)

1. Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am (2009) 23(5):1083-98. doi:10.1016/j.hoc.2009.07.010
2. Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2011) 117(23):6267-76. doi:10.1182/blood-2010-12-324004
3. Cavé H, van der Werfften Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Engl J Med (1998) 339(9):591-8. doi:10.1056/NEJM199808273390904
4. Nair RR, Tolentino J, Hazlehurst LA. The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem Pharmacol (2010) 80(5):602-12. doi:10.1016/j.bcp.2010.04.003
5. Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat (2009) 12(4-5):103-13. doi:10.1016/j.drup.2009.06.001
6. Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol (2011) 29(5):591-9. doi:10.1200/JCO.2010.31.0904
7. Kiel MJ, Acar M, Radice GL, Morrison SJ. Hematopoietic stem cells do not depend on N-cadherin to regulate their maintenance. Cell Stem Cell (2009) 4(2):170-9. doi:10.1016/j.stem.2008.10.005
8. Kiel MJ, Morrison SJ. Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol (2008) 8(4):290-301. doi:10.1038/nri2279
9. Manabe A, Coustan-Smith E, Behm FG, Raimondi SC, Campana D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood (1992) 79(9):2370-7.
10. Kumagai M, Manabe A, Pui CH, Behm FG, Raimondi SC, Hancock ML, et al. Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest (1996) 97(3):755-60. doi:10.1172/JCI118474
11. Mudry RE, Fortney JE, York T, Hall BM, Gibson LF. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood (2000) 96(5):1926-32.
12. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol (2004) 5(10):816-26. doi:10.1038/nrm1490
13. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell (2002) 110(6):673-87. doi:10.1016/S0092-8674(02)00971-6
14. Priestley GV, Scott LM, Ulyanova T, Papayannopoulou T. Lack of alpha4 integrin expression in stem cells restricts competitive function and self-renewal activity. Blood (2006) 107(7):2959-67. doi:10.1182/blood-2005-07-2670
15. Hara J, Matsuda Y, Fujisaki H, Tokimasa S, Ohta H, Osagi Y, et al. Expression of adhesion molecules in childhood B-lineage-cell neoplasms. Int J Hematol (2000) 72(1):69-73.
16. Liesveld JL, Winslow JM, Frediani KE, Ryan DH, Abboud CN. Expression of integrins and examination of their adhesive function in normal and leukemic hematopoietic cells. Blood (1993) 81(1):112-21.
17. Shalapour S, Hof J, Kirschner-Schwabe R, Bastian L, Eckert C, Prada J, et al. High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse. Haematologica (2011) 96(11):1627-35. doi:10.3324/haematol.2011.047993
18. Schwartz MA. Integrins and extracellular matrix in mechanotransduction. Cold Spring Harb Perspect Biol (2010) 2(12):a005066. doi:10.1101/cshperspect.a005066
19. Juliano RL. Signal transduction by cell adhesion receptors and the cytoskeleton: functions of integrins, cadherins, selectins, and immunoglobulin-superfamily members. Annu Rev Pharmacol Toxicol (2002) 42:283-323. doi:10.1146/annurev.pharmtox.42.090401.151133
20. Chigaev A, Zwartz GJ, Buranda T, Edwards BS, Prossnitz ER, Sklar LA. Conformational regulation of alpha 4 beta 1-integrin affinity by reducing agents. "Inside-out" signaling is independent of and additive to reduction-regulated integrin activation. J Biol Chem (2004) 279(31):32435-43. doi:10.1074/jbc.M404387200
21. Ye F, Snider AK, Ginsberg MH. Talin and kindlin: the one-two punch in integrin activation. Front Med (2014) 8(1):6-16. doi:10.1007/s11684-014-0317-3
22. Boudreau NJ, Jones PL. Extracellular matrix and integrin signalling: the shape of things to come. Biochem J (1999) 339(Pt 3):481-8. doi:10.1042/0264-6021:3390481
23. Parsons JT. Integrin-mediated signalling: regulation by protein tyrosine kinases and small GTP-binding proteins. Curr Opin Cell Biol (1996) 8(2):146-52. doi:10.1016/S0955-0674(96)80059-7
24. Herter J, Zarbock A. Integrin regulation during leukocyte recruitment. J Immunol (2013) 190(9):4451-7. doi:10.4049/jimmunol.1203179
25. Herter JM, Rossaint J, Block H, Welch H, Zarbock A. Integrin activation by P-Rex1 is required for selectin-mediated slow leukocyte rolling and intravascular crawling. Blood (2013) 121(12):2301-10. doi:10.1182/blood-2012-09-457085
26. McDonald PC, Fielding AB, Dedhar S. Integrin-linked kinase - essential roles in physiology and cancer biology. J Cell Sci (2008) 121(Pt 19):3121-32. doi:10.1242/jcs.017996
27. Liu W, Draheim KM, Zhang R, Calderwood DA, Boggon TJ. Mechanism for KRIT1 release of ICAP1-mediated suppression of integrin activation. Mol Cell (2013) 49(4):719-29. doi:10.1016/j.molcel.2012.12.005
28. Aoudjit F, Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract (2012) 2012:283181. doi:10.1155/2012/283181
29. Margadant C, Monsuur HN, Norman JC, Sonnenberg A. Mechanisms of integrin activation and trafficking. Curr Opin Cell Biol (2011) 23(5):607-14. doi:10.1016/j.ceb.2011.08.005
30. Iademarco MF, Barks JL, Dean DC. Regulation of vascular cell adhesion molecule-1 expression by IL-4 and TNF-alpha in cultured endothelial cells. J Clin Invest (1995) 95(1):264-71. doi:10.1172/JCI117650
31. Katayama Y, Hidalgo A, Peired A, Frenette PS. Integrin alpha4beta7 and its counterreceptor MAdCAM-1 contribute to hematopoietic progenitor recruitment into bone marrow following transplantation. Blood (2004) 104(7):2020-6. doi:10.1182/blood-2003-12-4157
32. Garcia-Pardo A, Wayner EA, Carter WG, Ferreira OC Jr. Human B lymphocytes define an alternative mechanism of adhesion to fibronectin. The interaction of the alpha 4 beta 1 integrin with the LHGPEILDVPST sequence of the type III connecting segment is sufficient to promote cell attachment. J Immunol (1990) 144(9):3361-6.
33. Craddock CF, Nakamoto B, Elices M, Papayannopoulou T. The role of CS1 moiety of fibronectin in VLA mediated haemopoietic progenitor trafficking. Br J Haematol (1997) 97(1):15-21. doi:10.1046/j.1365-2141.1997.d01-2120.x
34. Matsunaga T, Fukai F, Miura S, Nakane Y, Owaki T, Kodama H, et al. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia (2008) 22(2):353-60. doi:10.1038/sj.leu.2405017
35. Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med (2003) 9(9):1158-65. doi:10.1038/nm909
36. Hsieh YT, Gang EJ, Geng H, Park E, Huantes S, Chudziak D, et al. Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. Blood (2013) 121(10):1814-8. doi:10.1182/blood-2012-01-406272
37. Bayless KJ, Meininger GA, Scholtz JM, Davis GE. Osteopontin is a ligand for the alpha4beta1 integrin. J Cell Sci (1998) 111(Pt 9):1165-74.
38. Bogetto L, Gabriele E, Cariati R, Dolcetti R, Spessotto P, Doglioni C, et al. Bidirectional induction of the cognate receptor-ligand alpha4/VCAM-1 pair defines a novel mechanism of tumor intravasation. Blood (2000) 95(7):2397-406.
39. Yokosaki Y, Palmer EL, Prieto AL, Crossin KL, Bourdon MA, Pytela R, et al. The integrin alpha 9 beta 1 mediates cell attachment to a non-RGD site in the third fibronectin type III repeat of tenascin. J Biol Chem (1994) 269(43):26691-6.
40. Nilsson SK, Johnston HM, Whitty GA, Williams B, Webb RJ, Denhardt DT, et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood (2005) 106(4):1232-9. doi:10.1182/blood-2004-11-4422
41. Stier S, Ko Y, Forkert R, Lutz C, Neuhaus T, Grunewald E, et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med (2005) 201(11):1781-91. doi:10.1084/jem.20041992
42. Streuli CH, Akhtar N. Signal co-operation between integrins and other receptor systems. Biochem J (2009) 418(3):491-506. doi:10.1042/BJ20081948
43. Cabodi S, Moro L, Bergatto E, Boeri EE, Di SP, Turco E, et al. Integrin regulation of epidermal growth factor (EGF) receptor and of EGF-dependent responses. Biochem Soc Trans (2004) 32(Pt 3):438-42. doi:10.1042/BST0320438
44. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, et al. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature (1996) 379(6560):91-6. doi:10.1038/379091a0
45. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci U S A (1998) 95(19):11211-6. doi:10.1073/pnas.95.19.11211
46. Pasquali C, Bertschy-Meier D, Chabert C, Curchod ML, Arod C, Booth R, et al. A chemical proteomics approach to phosphatidylinositol 3-kinase signaling in macrophages. Mol Cell Proteomics (2007) 6(11):1829-41. doi:10.1074/mcp.T600066-MCP200
47. Legate KR, Montanez E, Kudlacek O, Fassler RILK. PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol (2006) 7(1):20-31. doi:10.1038/nrm1789
48. Guo W, Jiang H, Gray V, Dedhar S, Rao Y. Role of the integrin-linked kinase (ILK) in determining neuronal polarity. Dev Biol (2007) 306(2):457-68. doi:10.1016/j.ydbio.2007.03.019
49. Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, et al. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res (2007) 67(2):684-94. doi:10.1158/0008-5472.CAN-06-3166
50. Muranyi AL, Dedhar S, Hogge DE. Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. Leuk Res (2010) 34(10):1358-65. doi:10.1016/j.leukres.2010.01.006
51. Kornberg LJ, Earp HS, Turner CE, Prockop C, Juliano RL. Signal transduction by integrins: increased protein tyrosine phosphorylation caused by clustering of beta 1 integrins. Proc Natl Acad Sci U S A (1991) 88(19):8392-6. doi:10.1073/pnas.88.19.8392
52. Parsons JT, Parsons SJ. Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Curr Opin Cell Biol (1997) 9(2):187-92. doi:10.1016/S0955-0674(97)80062-2
53. Cary LA, Han DC, Guan JL. Integrin-mediated signal transduction pathways. Histol Histopathol (1999) 14(3):1001-9.
54. Schlaepfer DD, Hunter T. Integrin signalling and tyrosine phosphorylation: just the FAKs? Trends Cell Biol (1998) 8(4):151-7. doi:10.1016/S0962-8924(97)01172-0
55. Tybulewicz VL, Henderson RB. Rho family GTPases and their regulators in lymphocytes. Nat Rev Immunol (2009) 9(9):630-44. doi:10.1038/nri2606
56. Wary KK, Mainiero F, Isakoff SJ, Marcantonio EE, Giancotti FG. The adaptor protein Shc couples a class of integrins to the control of cell cycle progression. Cell (1996) 87(4):733-43. doi:10.1016/S0092-8674(00)81392-6
57. Wary KK, Mariotti A, Zurzolo C, Giancotti FG. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell (1998) 94(5):625-34. doi:10.1016/S0092-8674(00)81604-9
58. Liu S, Thomas SM, Woodside DG, Rose DM, Kiosses WB, Pfaff M, et al. Binding of paxillin to alpha4 integrins modifies integrin-dependent biological responses. Nature (1999) 402(6762):676-81. doi:10.1038/45264
59. Lim CJ, Han J, Yousefi N, Ma Y, Amieux PS, McKnight GS, et al. Alpha4 integrins are type I cAMP-dependent protein kinase-anchoring proteins. Nat Cell Biol (2007) 9(4):415-21. doi:10.1038/ncb1561
60. Rivera Rosado LA, Horn TA, McGrath SC, Cotter RJ, Yang JT. Association between alpha4 integrin cytoplasmic tail and non-muscle myosin IIA regulates cell migration. J Cell Sci (2011) 124(Pt 3):483-92. doi:10.1242/jcs.074211
61. Liu CC, Leclair P, Yap SQ, Lim CJ. The membrane-proximal KXGFFKR motif of alpha-integrin mediates chemoresistance. Mol Cell Biol (2013) 33(21):4334-45. doi:10.1128/MCB.00580-13
62. Abram CL, Lowell CA. The ins and outs of leukocyte integrin signaling. Annu Rev Immunol (2009) 27:339-62. doi:10.1146/annurev.immunol.021908.132554
63. Gaynon PS, Qu RP, Chappell RJ, Willoughby ML, Tubergen DG, Steinherz PG, et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse - the Children's Cancer Group Experience. Cancer (1998) 82(7):1387-95. doi:10.1002/(SICI)1097-0142(19980401)82:7<1387::AID-CNCR24>3.0.CO;2-1
64. Bradstock KF, Gottlieb DJ. Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease. Leuk Lymphoma (1995) 18(1-2):1-16. doi:10.3109/10428199509064917
65. Filshie R, Gottlieb D, Bradstock K. VLA-4 is involved in the engraftment of the human pre-B acute lymphoblastic leukaemia cell line NALM-6 in SCID mice. Br J Haematol (1998) 102(5):1292-300. doi:10.1046/j.1365-2141.1998.00899.x
66. Hazlehurst LA, Argilagos RF, Dalton WS. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. Br J Haematol (2007) 136(2):269-75. doi:10.1111/j.1365-2141.2006.06435.x
67. Fortney JE, Hall BM, Bartrug L, Gibson LF. Chemotherapy induces bcl-2 cleavage in lymphoid leukemic cell lines. Leuk Lymphoma (2002) 43(11):2171-8. doi:10.1080/1042819021000033024
68. Wang L, Fortney JE, Gibson LF. Stromal cell protection of B-lineage acute lymphoblastic leukemic cells during chemotherapy requires active Akt. Leuk Res (2004) 28(7):733-42. doi:10.1016/j.leukres.2003.10.033
69. Fortney JE, Zhao W, Wenger SL, Gibson LF. Bone marrow stromal cells regulate caspase 3 activity in leukemic cells during chemotherapy. Leuk Res (2001) 25(10):901-7. doi:10.1016/S0145-2126(01)00051-0
70. Nwabo Kamdje AH, Krampera M. Notch signaling in acute lymphoblastic leukemia: any role for stromal microenvironment? Blood (2011) 118(25):6506-14. doi:10.1182/blood-2011-08-376061
71. Bertrand FE, Spengemen JD, Shelton JG, McCubrey JA. Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support. Leukemia (2005) 19(1):98-102. doi:10.1038/sj.leu.2403560
72. Pillozzi S, Masselli M, De LE, Accordi B, Cilia E, Crociani O, et al. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood (2011) 117(3):902-14. doi:10.1182/blood-2010-01-262691
73. Ma H, Cheng L, Hao K, Li Y, Song X, Zhou H, et al. Reversal effect of ST6GAL 1 on multidrug resistance in human leukemia by regulating the PI3K/Akt pathway and the expression of P-gp and MRP1. PLoS One (2014) 9(1):e85113. doi:10.1371/journal.pone.0085113
74. Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T, et al. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia (2007) 21(3):427-38. doi:10.1038/sj.leu.2404523
75. Jacamo R, Chen Y, Wang Z, Ma W, Zhang M, Spaeth EL, et al. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance. Blood (2014) 123(17):2691-702. doi:10.1182/blood-2013-06-511527
76. Elices MJ. The integrin alpha 4 beta 1 (VLA-4) as a therapeutic target. Ciba Found Symp (1995) 189:79-85.
77. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov (2010) 9(10):804-20. doi:10.1038/nrd3266
78. Millard M, Odde S, Neamati N. Integrin targeted therapeutics. Theranostics (2011) 1:154-88. doi:10.7150/thno/v01p0154
79. Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci (2012) 33(7):405-12. doi:10.1016/j.tips.2012.04.002
80. Chigaev A, Wu Y, Williams DB, Smagley Y, Sklar LA. Discovery of very late antigen-4 (VLA-4, alpha4beta1 integrin) allosteric antagonists. J Biol Chem (2011) 286(7):5455-63. doi:10.1074/jbc.M110.162636
81. Jackson DY. Alpha 4 integrin antagonists. Curr Pharm Des (2002) 8(14):1229-53. doi:10.2174/1381612023394737
82. Yu Y, Schurpf T, Springer TA. How natalizumab binds and antagonizes alpha4 integrins. J Biol Chem (2013) 288(45):32314-25. doi:10.1074/jbc.M113.501668
83. Weber MS, Menge T, Lehmann-Horn K, Kronsbein HC, Zettl U, Sellner J, et al. Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. Curr Pharm Des (2012) 18(2):209-19. doi:10.2174/138161212799040501
84. Clifford DB, De LA, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol (2010) 9(4):438-46. doi:10.1016/S1474-4422(10)70028-4
85. Neumann F, Zohren F, Haas R. The role of natalizumab in hematopoietic stem cell mobilization. Expert Opin Biol Ther (2009) 9(8):1099-106. doi:10.1517/14712590903055011
86. Bonig H, Wundes A, Chang KH, Lucas S, Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood (2008) 111(7):3439-41. doi:10.1182/blood-2007-09-112052
87. Tilg H, Kaser A. Vedolizumab, a humanized mAb against the alpha4beta7 integrin for the potential treatment of ulcerative colitis and Crohn's disease. Curr Opin Investig Drugs (2010) 11(11):1295-304.
88. Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology (2012) 20(1):1-18. doi:10.1007/s10787-011-0104-6
89. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol (2008) 6(12):1370-7. doi:10.1016/j.cgh.2008.06.007
90. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med (2005) 352(24):2499-507. doi:10.1056/NEJMoa042982
91. Rettig MP, Ansstas G, DiPersio JF. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia (2012) 26(1):34-53. doi:10.1038/leu.2011.197
92. Ramirez P, Rettig MP, Uy GL, Deych E, Holt MS, Ritchey JK, et al. Bio5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood (2009) 114(7):1340-3. doi:10.1182/blood-2008-10-184721
93. Becker PS, Appelbaum FR, Chien S, Zhao X, Bonig H, Mukasa R, et al. Oral small molecule inhibitor of VLA-4 overcomes adhesion mediated chemotherapy resistance of acute myeloid leukemia (AML) blasts in vitro, without impairment of normal blood cell recovery when combined with chemotherapy in vivo. Blood (2008) 112:858.
94. Sugiura T, Kageyama S, Andou A, Miyazawa T, Ejima C, Nakayama A, et al. Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis (2013) 7(11):e533-42. doi:10.1016/j.crohns.2013.03.014
95. Miller DH, Weber T, Grove R, Wardell C, Horrigan J, Graff O, et al. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2012) 11(2):131-9. doi:10.1016/S1474-4422(11)70299-X
96. Hijazi Y, Welker H, Dorr AE, Tang JP, Blain R, Renzetti LM, et al. Pharmacokinetics, safety, and tolerability of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers. J Clin Pharmacol (2004) 44(12):1368-78. doi:10.1177/0091270004270147
97. Hijazi Y, Welker H, Dorr AE, Frank K, Renzetti LM, Patel I. Evaluation of the effect of multiple-dose administration of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist on the major CYP isoform activities in healthy volunteers. Eur J Clin Pharmacol (2006) 62(1):83-5. doi:10.1007/s00228-005-0067-x
98. Wolf C, Sidhu J, Otoul C, Morris DL, Cnops J, Taubel J, et al. Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study. PLoS One (2013) 8(3):e58438. doi:10.1371/journal.pone.0058438
99. Chanteux H, Rosa M, Delatour C, Prakash C, Smith S, Nicolas JM. In vitro hydrolysis and transesterification of CDP323, an alpha4beta1/alpha4beta7 integrin antagonist ester prodrug. Drug Metab Dispos (2014) 42(1):153-61. doi:10.1124/dmd.113.054049
100. Chen L, Tilley J, Trilles RV, Yun W, Fry D, Cook C, et al. N-acyl-l-phenylalanine derivatives as potent VLA-4 antagonists that mimic a cyclic peptide conformation. Bioorg Med Chem Lett (2002) 12(2):137-40. doi:10.1016/S0960-894X(01)00711-9
101. Lin K, Ateeq HS, Hsiung SH, Chong LT, Zimmerman CN, Castro A, et al. Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses. J Med Chem (1999) 42(5):920-34. doi:10.1021/jm980673g
102. Leone DR, Giza K, Gill A, Dolinski BM, Yang W, Perper S, et al. An assessment of the mechanistic differences between two integrin alpha 4 beta 1 inhibitors, the monoclonal antibody TA-2 and the small molecule Bio5192, in rat experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther (2003) 305(3):1150-62. doi:10.1124/jpet.102.047332
103. Norris V, Choong L, Tran D, Corden Z, Boyce M, Arshad H, et al. Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol (2005) 116(4):761-7. doi:10.1016/j.jaci.2005.04.045
104. Vanderslice P, Woodside DG, Caivano AR, Decker ER, Munsch CL, Sherwood SJ, et al. Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin alpha4beta1. Biochem Biophys Res Commun (2010) 400(4):619-24. doi:10.1016/j.bbrc.2010.08.114
105. Vanderslice P, Biediger RJ, Woodside DG, Brown WS, Khounlo S, Warier ND, et al. Small molecule agonist of very late antigen-4 (VLA-4) integrin induces progenitor cell adhesion. J Biol Chem. 2013; 288(27):19414-28. doi:10.1074/jbc.M113.479634
106. Wayner EA, Garcia-Pardo A, Humphries MJ, McDonald JA, Carter WG. Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J Cell Biol (1989) 109(3):1321-30. doi:10.1083/jcb.109.3.1321
107. Mould AP, Wheldon LA, Komoriya A, Wayner EA, Yamada KM, Humphries MJ. Affinity chromatographic isolation of the melanoma adhesion receptor for the IIICS region of fibronectin and its identification as the integrin alpha 4 beta 1. J Biol Chem (1990) 265(7):4020-4.
108. Komoriya A, Green LJ, Mervic M, Yamada SS, Yamada KM, Humphries MJ. The minimal essential sequence for a major cell type-specific adhesion site (CS1) within the alternatively spliced type III connecting segment domain of fibronectin is leucine-aspartic acid-valine. J Biol Chem (1991) 266(23):15075-9.
109. Woodside DG, Vanderslice P. Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive pulmonary disease. BioDrugs (2008) 22(2):85-100. doi:10.2165/00063030-200822020-00002
110. Kenyon NJ, Liu R, O'Roark EM, Huang W, Peng L, Lam KS. An alpha4beta1 integrin antagonist decreases airway inflammation in ovalbumin-exposed mice. Eur J Pharmacol (2009) 603(1-3):138-46. doi:10.1016/j.ejphar.2008.11.063
111. Peng L, Liu R, Marik J, Wang X, Takada Y, Lam KS. Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. Nat Chem Biol (2006) 2(7):381-9. doi:10.1038/nchembio798
112. Shah B, Jensen BK, Zhang J, Hunt T, Rohatagi S. Effect of food on pharmacokinetics of an inhaled drug: a case study with a VLA-4 antagonist, HMR1031. J Clin Pharmacol (2003) 43(12):1341-9. doi:10.1177/0091270003258172
113. Diamant Z, Kuperus J, Baan R, Nietzmann K, Millet S, Mendes P, et al. Effect of a very late antigen-4 receptor antagonist on allergen-induced airway responses and inflammation in asthma. Clin Exp Allergy (2005) 35(8):1080-7. doi:10.1111/j.1365-2222.2005.02296.x
114. Setoguchi M, Iimura S, Sugimoto Y, Yoneda Y, Chiba J, Watanabe T, et al. A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid. Bioorg Med Chem (2013) 21(1):42-61. doi:10.1016/j.bmc.2012.11.003